drugset
drugset / Trial / NCT05336721

A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

NCT05336721 ↗

Phase 2 Terminated 9 enrolled Chipscreen Biosciences, Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This study is to evaluate the preliminary efficacy and safety of chiauranib in combine with capecitabine in advanced triple-negative breast cancer failed to prior anthracyclines and taxanes therapy

Timeline

Start
2021-11-05
Primary completion
2024-10-31
Completion
2024-11-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1000 mg/m2 —
Subject IBCASERTIB Small molecule 25 mg Oral
Subject IBCASERTIB Small molecule 35 mg Oral
Subject IBCASERTIB Small molecule 50 mg Oral

Indications

triple-negative breast carcinoma